Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

NCT04462471 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Carcinoma
Thyroid Cancer
Thyroid Cancer, Follicular
Thyroid Cancer (Follicular Cell)
Thyroid Cancer, Papillary
BRAF V600E Mutation Positive

Interventions

DIAGNOSTIC_TEST: I-124 PET/CT lesion dosimetry
DRUG: Vemurafenib
DRUG: Copanlisib

Sponsor

Memorial Sloan Kettering Cancer Center